Malcolm Spicer, Managing Editor – US
Latest From Malcolm Spicer
FTDA and FTC warn Patriot Supreme about noncompliant claims on its website and social media pages promoting CBD to prevent or treat infections from the coronavirus. However, a release Patriot Supreme distributed in July promoting CBD as a COVID-19 remedy remains in online circulation.
“To the extent these claims pertain to the ingestion of peanuts, they are not consistent with the claim in the  Letter of Enforcement Discretion FDA issued in response to a petition for a qualified health claim for ground peanuts and reduced risk of developing peanut allergy,” state CFSAN officials.
Warnings state each’s firm products “are concerning from a public health perspective because they are labeled to contain the ingredients bloodroot (Sanguinaria canadensis) and zinc chloride … known corrosive agents.” The combination results in a corrosive topical agent capable of indiscriminately damaging healthy and diseased tissue alike.
Results of a JAMA study on why consumers say they use CBD supplements and an accompanying commentary emphasize that FDA should eliminate "unsupported claims of medical benefit” for CBDs and other cannabinoids.
In Drug Safety Communication, FDA says it is requiring labeling changes for Rx as well as OTC NSAIDs due to risk of rare but serious kidney problems in an unborn baby.
FDA again sets expected costs at level supplement industry repeatedly has said drastically underestimates spending on preparing and submitting NDI notifications. But FDA says developing scientific evidence to support a notification is separate from submitting the information to the agency.